Video
Dr. Goy Discusses Single-Agent Ibrutinib in MCL
Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses single-agent ibrutinib (Imbruvica) in mantle cell lymphoma.
Andre Goy, MD, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses single-agent ibrutinib (Imbruvica) in mantle cell lymphoma (MCL).
A long-term follow-up of single-agent ibrutinib was presented at the 2017 ASH Annual Meeting. Goy reports that the complete response rate was up to 26%. Additionally, at 3 years, one-quarter of patients still had not progressed.
However, work still needs to be done to determine which patients would benefit best from ibrutinib, Goy adds.
